SCHEMBL12326825

SCHEMBL12326825

Cc1ccc(CNC(=O)c2ccc(C)nc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.59
KDM4E B2RXH2 2/20 0.58
MAPT P10636 2/20 0.58
ALDH1A1 P00352 2/20 0.58
HTT P42858 2/20 0.58
HDAC1 Q13547 3/20 0.57
HDAC6 Q9UBN7 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 1/20 0.56
KMT2A Q03164 3/20 0.55
MAPK14 Q16539 2/20 0.55
MEN1 O00255 2/20 0.55
POLB P06746 2/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
MCL1 Q07820 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
CYP3A4 P08684 2/20 0.53
MMP13 P45452 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13947100 0.91 MMP13 (0.59) NAMPTKDM4EMAPTALDH1A1HTT
SCHEMBL8376682 0.90 KDM4E (0.57) NAMPTKDM4EMAPTALDH1A1HDAC1
SCHEMBL12444444 0.88 L3MBTL1 (0.58) KDM4EALDH1A1HDAC1HDAC6SMN1; SMN2
SCHEMBL25044558 0.88 L3MBTL1 (0.69) KDM4EALDH1A1HDAC1HDAC6LMNA
SCHEMBL7845641 0.86 EPHX2 (0.66) NAMPTMAPTALDH1A1HTTHDAC6
SCHEMBL31043628 0.86 KDM4E (0.53) NAMPTKDM4EALDH1A1HTTHDAC1
SCHEMBL12326827 0.85 NPC1 (0.63) NAMPTKDM4EMAPTHDAC1HDAC6
SCHEMBL31029156 0.85 HTT (0.55) NAMPTKDM4EMAPTALDH1A1HTT
SCHEMBL20319899 0.84 POLB (0.52) NAMPTKDM4EMAPTHDAC1HDAC6
SCHEMBL13932522 0.84 ALDH1A1 (0.78) NAMPTKDM4EMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 EP disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 NAMPT 2852/4885KDM4E 2465/4885MAPT 3817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.